CytomX Therapeutics (CTMX) Net Income towards Common Stockholders Growth (5y) (2019 - 2026)
CytomX Therapeutics (CTMX) Net Income towards Common Stockholders Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | CytomX Therapeutics | 582.34 Mn | 235.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.79% |
| Dec 31, 2025 | 1.14% |
| Sep 30, 2025 | 10.68% |
| Jun 30, 2025 | 63.95% |
| Mar 31, 2025 | 19.87% |
| Dec 31, 2024 | 17.98% |
| Sep 30, 2024 | 17.52% |
| Jun 30, 2024 | 25.75% |
| Mar 31, 2024 | 24.38% |
| Dec 31, 2023 | 15.17% |
| Sep 30, 2023 | 16.30% |
| Jun 30, 2023 | 39.53% |
| Mar 31, 2023 | 26.55% |
| Dec 31, 2022 | -74.39% |
| Sep 30, 2022 | -23.18% |
| Jun 30, 2022 | -3.19% |
| Mar 31, 2022 | -31.10% |
| Dec 31, 2021 | -19.93% |
| Sep 30, 2021 | -16.14% |
| Jun 30, 2021 | -13.53% |